Meracle

Meracle increase the efficacy of medication delivered into the lungs of chronic respiratory patients, while tracking intake data to augment the assessment of treatment outcomes

Operating in health based in Tokyo, Japan, Meracle was founded in 2018.

Profile

"Meracle is a pioneering deeptech company focused on enhancing the efficacy of medication delivery for chronic respiratory patients while monitoring intake data to improve treatment outcomes. By optimizing therapy delivery in a safe and efficient manner, Meracle provides relief and assurance to patients with respiratory conditions. The company's user-friendly digital platform facilitates seamless collaboration between patients and healthcare providers, ensuring optimal treatment adherence. Originally identified by respiratory specialists at the National University Hospital in Singapore, the need for improved medication delivery stemmed from patients experiencing stagnant or worsening conditions due to incorrect techniques and suboptimal compliance. Supported by SG$1.5 million in non-dilutive grants from prestigious institutions, including the National Research Foundation and National University of Singapore, Meracle has achieved significant milestones in developing this innovative solution. Motivated by personal experiences with asthma within their own families, the team at Meracle is dedicated to bringing this transformative technology to patients in need."

As a business in health, Meracle is listed here with the public details available about it.

The business is associated with Tokyo, Japan.

It is recorded at the Plug and Play portfolio startup stage.

The company reports a headcount in the 1 - 10 range.

Website: www.meraclehealth.com